High-risk myelodysplastic syndrome (MDS): first results of international phase 2 study with oral farnesyl transferase inhibitor R115777 - Kurzrock, Fenaux, et al.Kurzrock R, Fenaux P, Raza A, et al. High-risk myelodysplastic syndromes (MDS): first results of interna- tional phase 2 study ...
Smoking may contribute to genetic mutations and disease progression in myelodysplastic syndromes, a recent study found. Results from a recent study showed that, in patients with myelodysplastic syndrome (MDS), tobacco smoking can influence the disease’s multistep molecular pathogenesis through g...
骨髓 原始细胞<5% 原始细胞<5%,伴环形铁粒幼细胞增多>15% 原始细胞5%--20%原始细胞>20%<30%:或幼粒细胞出现Auer小体 原始细胞5%--20% BennettJM，etal.Proposalsfortheclassificationofthemyelodysplastic syndrome.Br.J.Haematol.1982；51：189-199 第五页，共48页。类型RCUDRARSRCMD RAEB-1RAEB-2 ...
Myelodysplastic Syndrome with Excess Blasts and Erythroid Predominance (MDS-EB-E) With NPM1 Mutation and P53 Expression Satarupa Mohapatra, DM; Somanath Padhi, MD*; Prabodha Kumar Das, MD, FRCPA; Gaurav Chhabra, MD Department of Pathology and Laboratory Medicine; and Medical Oncology/Hematology,...
Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome. Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome. Investigators found that venetocla...
Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study Therapy of myelodysplastic syndrome (MDS) with azacitidine given in combination with etanercept: a phase II study. Blood. 2007; 110 :435a. Abstract 1452.Holsinger et al., " Therapy ...
Myelodysplastic syndrome (MDS) is a very heterogeneous clonal disorder. Patients with “higher-risk” MDS, defined by specific recurrent genetic abnormalities, have a poor prognosis because of a high risk of progression to secondary acute myeloid leukemia with low chemosensitivity. Allogeneic hematopoietic...
Venetoclax (Venclexta) in combination with 10-day decitabine demonstrated safety and efficacy in older/unfit patients with newly diagnosed acute myeloid leukemia (AML), patients with relapsed/refractory AML, and patients with high-risk myelodysplastic syndrome (MDS), according to data from a phas...
Grövdal M, Khan R, Aggerholm A et al (2007) Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res 13:7107–7112 Article PubMed Google...
AML, acute myeloid leukemia; AZA, azacitidine; BM-CR, bone marrow complete response; CMML, chronic myelomonocytic leukemia; CR, complete response; CRi, morphologic CR with incomplete blood count; MDS, myelodysplastic syndrome; PAN, panobinostat; WT, wild type. Leukemia (2017) 2799 – 2806 ...